Weaker, Not Just Lighter: Monitoring Strength and Function, Not Lean Mass, During GLP-1 Weight Loss

More on GLP-1 receptor agonists

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• Body composition shifts follow sex-specific paths across adulthood

  GeroScience · 4 Oct 2026